IS7755A - Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín - Google Patents

Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín

Info

Publication number
IS7755A
IS7755A IS7755A IS7755A IS7755A IS 7755 A IS7755 A IS 7755A IS 7755 A IS7755 A IS 7755A IS 7755 A IS7755 A IS 7755A IS 7755 A IS7755 A IS 7755A
Authority
IS
Iceland
Prior art keywords
benzylaminoquinuclidine
benzhydryl
cis
preparation
Prior art date
Application number
IS7755A
Other languages
English (en)
Icelandic (is)
Inventor
C. Nugent Thomas
Seemayer Robert
Original Assignee
Pfizer Products Inc.
Dsm Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc., Dsm Pharmaceuticals, Inc. filed Critical Pfizer Products Inc.
Publication of IS7755A publication Critical patent/IS7755A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS7755A 2002-10-16 2005-03-17 Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín IS7755A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41905102P 2002-10-16 2002-10-16
PCT/US2003/032275 WO2004035575A1 (en) 2002-10-16 2003-10-10 Process for the preparation of (s,s)-cis-2-benzhydryl-3-benzylaminoquinuclidine

Publications (1)

Publication Number Publication Date
IS7755A true IS7755A (is) 2005-03-17

Family

ID=32108014

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7755A IS7755A (is) 2002-10-16 2005-03-17 Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín

Country Status (21)

Country Link
US (2) US6861526B2 (enExample)
EP (1) EP1551833A4 (enExample)
JP (1) JP2006506368A (enExample)
KR (1) KR100739901B1 (enExample)
CN (1) CN100418964C (enExample)
AP (1) AP2005003288A0 (enExample)
AR (1) AR041587A1 (enExample)
AU (1) AU2003277353B2 (enExample)
BR (1) BR0315335A (enExample)
CA (1) CA2500635A1 (enExample)
EA (1) EA008192B1 (enExample)
HR (1) HRP20050328A2 (enExample)
IS (1) IS7755A (enExample)
MX (1) MXPA05004058A (enExample)
PA (1) PA8586601A1 (enExample)
PE (1) PE20040777A1 (enExample)
PL (1) PL376218A1 (enExample)
TN (1) TNSN05111A1 (enExample)
UY (1) UY28024A1 (enExample)
WO (1) WO2004035575A1 (enExample)
ZA (1) ZA200502411B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
NZ548236A (en) * 2004-01-30 2010-02-26 Pfizer Prod Inc Compositions comprising (2S.3S) (2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-alkyl-2-methoxy-benzyl)-amine derivatives
AU2005210259A1 (en) * 2004-02-02 2005-08-18 Pfizer Products Inc. Process for preparation of 1-(2S,3S)-2-benzhydr yl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN108341812A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 一种含奎宁环化合物的制备方法
CN108341811A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 马罗皮坦杂质的制备方法
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
WO1990005525A1 (en) 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5138060A (en) 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
DE69232334T2 (de) 1991-05-22 2002-11-14 Pfizer Inc., New York Substituierte 3-aminochinuclidine
SK278788B6 (sk) * 1991-05-31 1998-02-04 Pfizer Inc. Chinuklidínové deriváty, spôsob ich prípravy a pou
EP1114823A3 (en) 1992-08-19 2001-07-18 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
JP2656699B2 (ja) 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
US5604241A (en) * 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists
JP2656700B2 (ja) 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
DK0668863T3 (da) * 1992-11-12 1997-06-30 Pfizer Quinuclidinderivat som substans P-antagonist
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
MX9706944A (es) 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.

Also Published As

Publication number Publication date
EA008192B1 (ru) 2007-04-27
UY28024A1 (es) 2004-05-31
KR100739901B1 (ko) 2007-07-13
CN100418964C (zh) 2008-09-17
US20050085641A1 (en) 2005-04-21
AU2003277353A1 (en) 2004-05-04
US6861526B2 (en) 2005-03-01
EP1551833A1 (en) 2005-07-13
PE20040777A1 (es) 2004-11-20
HRP20050328A2 (en) 2005-06-30
PL376218A1 (en) 2005-12-27
WO2004035575A8 (en) 2005-05-12
TNSN05111A1 (en) 2007-05-14
KR20050083764A (ko) 2005-08-26
AP2005003288A0 (en) 2005-06-30
BR0315335A (pt) 2005-08-16
AU2003277353B2 (en) 2007-08-09
MXPA05004058A (es) 2005-06-08
JP2006506368A (ja) 2006-02-23
EA200500650A1 (ru) 2005-10-27
US20040116704A1 (en) 2004-06-17
EP1551833A4 (en) 2010-06-02
CA2500635A1 (en) 2004-04-29
PA8586601A1 (es) 2005-02-04
AR041587A1 (es) 2005-05-26
HK1078087A1 (en) 2006-03-03
WO2004035575A1 (en) 2004-04-29
ZA200502411B (en) 2006-05-31
CN1705664A (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
IS7755A (is) Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín
IS8516A (is) Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum
IS2722B (is) 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
DK1546122T3 (da) Fremgangsmåde til fremstilling af valsartan
ZA200402695B (en) Process for the preparation of methanol.
DE60305332D1 (de) IMIDAZOi1,2-AöPYRIDINE
IS7239A (is) Aðferð til framleiðslu á essítalóprami
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
IS7163A (is) Aðferðir til meðhöndlunar á lungnasjúkdómi
FI20030383A0 (fi) Menetelmä katalyytin valmistamiseksi
DE60324703D1 (de) Barbitursäure derivaten.
DE60324071D1 (de) Katalysatorherstellungsverfahren
NO20052471D0 (no) Fremgangsmate for fremstilling av 3-metyltiopropanal.
NO20034597D0 (no) Fremgangsmåte for fremstilling av cantaxantin
EP1565448A4 (en) PROCESS FOR THE PREPARATION OF 10H-DIBENZOçB, F] ç1,4] THIAZEPIN-11-ON
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater
NO20044332L (no) Forbedret fremgangsmate for fremstilling av nevirapine
DK1503995T3 (da) Fremgangsmåde til fremstilling af substituerede phenylsulfonylurinstoffer
ITMI20030346A1 (it) Procedimento per la produzione di mesitilene.
EP1477477A4 (en) PROCESS FOR THE PREPARATION OF CAROTENOIDS
IT1338456B1 (it) Procedimento per la preparazione di alchiluree da o ,d-dimetil ditiocarbonato
NO20052593D0 (no) Kontinuerlig fremgangsmate for fremstilling av fruktopyranose sulfamat derivater.
NO20052392L (no) Fremgangsmate for fremstilling av acetylenforbindelser.
AU2003284212A8 (en) Process for the preparation of (s,s)-cis-2-phenyl-3-aminopiperidine
NO20051594L (no) Prosess for fremstilling av (s,s)-cis-2-benzhydryl-3-benzylaminokinukludin